Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II, Placebo-controlled, Multicenter Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas

NCT02389244 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT02389244
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02389244 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II, Placebo-controlled, Multicenter Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas
Lead sponsor
UNICANCER
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2014
Completion date
September 3, 2025
Enrollment
163 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

chondroma, chondrosarcomas, cic-rearranged sarcoma, ewing sarcomas, osteosarcomas